The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | TOURMALINE-MM1 updates: importance and challenges of adjusting for subsequent therapies
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses findings from the Phase III TOURMALINE-MM1 study (NCT01564537), highlighting how blinded treatment in such trials may lead to maladjustment of subsequent therapies. This may potentially impact overall survival (OS) as an endpoint, and Dr Ramasamy suggests methodologies to overcome this. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
